LONDON, December 19, 2014 /PRNewswire/ --
TODAY, AEGATE, the leader in medicine verification and authentication services in the World announced the appointment of Peter Fox as Chief Technology Officer and Anthony R. Vonsée, as Chief Channels and Partner Officer.
Peter has served as Development Director for Datanomic since 2004 through to its acquisition by Oracle in 2011.
Prior to Datanomic, Peter was Development Director at Geneva and subsequently Convergys, a world renowned billing system for Telecom Operators overseeing all UI development and group architecture for US offices.
He has had a vast experience of running teams around the world, from the USA, to Europe to India. He has also worked extensively in the USA and Australia.
Peter holds a Bachelor of Science in Pure and Applied Physics from the Institute of Technology at the University of Manchester and has a MSc from Aston University in Birmingham.
Anthony Vonsée joins AEGATE from Cisco, where he held a Senior Business Development position in Cisco's Worldwide Sales organization responsible for Strategy, Planning and Sales transformation, developing innovative go-to-market strategies for the sales force and its partners. Before Cisco, Mr. Vonsée held leadership positions with KPN Telecoms of the Netherlands, AT&T, Digital Equipment and Coopers & Lybrand.
Mark de Simone, CEO at AEGATE commented: "Today we have again moved to increase our footprint, reach and resource to service European and global markets, alongside continuing to provide, maintain and increase the value of our market leading medicine authentication and verification services"
"Anthony is a highly creative and respected business leader with high levels of integrity, who has developed strong, long-term relationships with customers, partners, captains of industry and government leaders across the world with a consistent track record of results. He will drive the integration of our partner systems for the existing and new services and ensure partner readiness for our new suite of services, by providing training, partner incentive programs, partner quality assurance and well as provide partner support.
Peter is a software industry leader with a proven track record in developing and running large transaction-intensive services in a number of industries. The ability to develop and run services in a very large scale, secure, reliable, trusted system is at the core of Aegate .
Sir David Cooksey, Chairman of AEGATE: "I am very excited about this announcement as it shows that AEGATE is able to attract the best talent in the world, to drive our expanding partner eco-system , while creating new revenue streams for those partners."
De Simone added "I am very excited about the opportunity to drive the company vision of a safe and informed medicine network in Europe and I am looking forward to meeting our European partners at the AEGATE Symposium in Amsterdam, the Netherlands , February 19-20."
For more information about the AEGATE Symposium and to register, please visit http://bit.ly/ag8Sypm14en
About the EU Falsified Medicines Directive
European legislation passed in 2011 and aimed at stemming the flow of falsified medicines reaching the open market within the European Economic area, the EU Falsified Medicines Directive (FMD 2011/62/EU) will, within a few years, completely change the landscape of the European pharmaceutical business model. The scope of the Directive places new obligations on all branches of the industry - manufacturers, generics producers, contract packers, re-packers and importers - amongst which is the unique identification of products at unit of sale level.
With a documented history of some 3 billion medicines scanned to date with an average rate of 200k transactions per hour across 15k dispensing points, Aegate is the principal active market leader in medicines verification. Aegate's Reach, Assure and Protect services meets the needs of all stakeholders. Supported internationally by manufacturers and pharmacists alike, Aegate is a European company with offices in Belgium, Italy, Switzerland and the UK. Our mission is to protect patients from falsified, recalled or expired medicines.
We operate a highly secure real-time system to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation for falsified medicines. The Aegate network also supports messaging services that provide additional information for the pharmacist at the point of dispense, such as regulatory or drug safety advice and patient education or adherence information.
For more information on Aegate, please visit http://www.aegate.com
Media contact information:
Commercial Director Aegate Ltd
Cambridge Technology Centre
Melbourn SG8 6DP UK